Tania Simoncelli: Should you be able to patent a human gene?
Tania Simoncelli advises the White House on science and technology policy. Full bio
Double-click the English transcript below to play the video.
as the organization's science advisor.
just a little bit discouraged.
to my colleague Chris Hansen's office.
for more than 30 years,
knowledge and insights.
that I was feeling a little bit stuck.
a number of issues
and civil liberties -- super interesting.
these issues in a much bigger way,
make a difference.
to the chase, and he says,
looking at, what are the top five?"
for lie detection, and ...
on part of the human body?
and sent Chris three articles.
he came bursting in my office.
about patent law
but I wasn't even a lawyer,
before we could file a lawsuit.
exactly what was patented
dozens of claims,
are to so-called "isolated DNA" --
that has been removed from a cell.
the gene in your body,
of the gene requires that it be isolated.
to a particular gene that they isolated,
version of that gene.
your gene to your doctor
has the right to stop anyone
in research or clinical testing.
was harming patients.
if left untreated,
genes associated with this condition
and they never offered it.
threatened to sue the lab
and were harming patients.
we could challenge them?
through a long line of cases,
are not patent eligible.
elements of the periodic table.
and must remain free to all
of all of our proteins,
and a law of nature,
to speak with many different experts --
lawyers, patent lawyers.
as a matter of policy,
as a matter of law.
a gene-patent challenge
had been issuing these patents
of patents on human genes.
entrenched in the status quo,
around this practice,
had been introduced
to overturn these patents.
to shy away from a challenge,
just isn't enough,"
to take on this fight.
Company A sues Company B
obscure technical issue.
in that kind of case,
was much bigger than that.
medical progress,
to develop a case
your typical patent case --
a gene-patent holder
of plaintiffs and experts
were harming patients and innovation.
to sue in Myriad Genetics,
in Salt Lake City, Utah.
along these genes
at a significantly increased risk
in the United States.
that were offering BRCA testing to stop.
scientific community.
to include additional mutations
by a team of researchers in France.
that during that period,
undergoing testing
that should have been positive.
developed breast cancer at age 40
most likely didn't run in the family,
didn't need to be tested.
with advanced-stage ovarian cancer.
was among the 12 percent
could have been prevented.
of plaintiffs and experts
highly committed plaintiffs:
cease and desist letters,
that collectively represented
and medical professionals,
couldn't afford Myriad's test,
a second opinion but could not,
we had in preparing the case
to communicate the science.
was not an invention,
were products of nature,
of basic concepts, like:
and why isn't that an invention?
with our plaintiffs and experts,
of explaining these concepts
on the use of metaphors,
the process for mining the gold,
of hard work and effort
it's still gold.
for all sorts of things
for when it was in the mountain;
out of it for example --
it's still gold.
and we're ready to file our case.
in the Southern District of New York,
to Judge Robert Sweet.
issued his opinion --
he described the science in the case.
it was pretty good,
understanding of this issue
how this had happened.
working for him at the time,
for the Federal Circuit.
submitted a brief on Myriad's side.
to its own patent office,
that states that is has
in light of the district court's opinion,
is not patent eligible.
for the Federal Circuit
very, very pro-patent.
biological theory --
a new chemical --
so it came out of the blue.
that isolated DNA is a product of nature.
to shake up the biotech industry."
by the Supreme Court.
that you want the Court to answer.
of a super-long paragraph,
with lots and lots of clauses,
the shortest question presented ever.
what I thought of these words,
'Is isolated DNA patentable?'"
the very same reaction that I had
to me seven years ago."
argue with that.
about one percent
and it was really, really exciting --
since 2:30 in the morning
on the courthouse steps.
as I walked into the courtroom
at a sea of friendly faces:
deeply personal stories,
of time out of their busy careers
briefs in the case.
of the Human Genome Project,
of DNA himself,
to gene patenting as "lunacy."
represented in this room
to make this day a reality
the Supreme Court justices grapple
and feisty exchanges,
as our legal team had done
from the Amazon.
from carving a baseball bat from a tree.
favorite moments,
to be "just nature sitting there."
leaving the courtroom that day,
anticipated the outcome:
is a product of nature,
it has been isolated.
for the BRCA genes.
at a lower price than Myriad's.
a more comprehensive test
goes far beyond Myriad.
of allowing patents on human genes
to biomedical discovery and innovation.
like Abigail, Kathleen and Eileen
issued its decision,
Chris and I went to visit
whether to bring this case.
a small stuffed animal.
to take that risk
the right thing.
from the start to finish,
that we bridged,
ABOUT THE SPEAKER
Tania Simoncelli - Policy expertTania Simoncelli advises the White House on science and technology policy.
Why you should listen
Tania Simoncelli is Assistant Director for Forensic Science in the White House Office of Science and Technology Policy (OSTP). She came to OSTP from the U.S. Food and Drug Administration (FDA), where she served as Senior Advisor in the Office of Medical Products and Tobacco, providing guidance and leadership on complex initiatives that required coordination across the centers for drugs, biologics, medical devices and tobacco products. Prior to this role, she served for two years as Special Assistant to FDA Commissioner Margaret Hamburg, where she advised the Commissioner and her staff on a wide range of issues, including nutrition labeling, food safety, genetically modified foods, scientific integrity, drug safety communication, direct-to-consumer genetic testing and personalized medicine.
From 2003-2010, Simoncelli worked as the Science Advisor to the American Civil Liberties Union, where she guided the organization’s responses to cutting-edge developments in science and technology that pose challenges for civil liberties. In this capacity, she spearheaded the development of ACLU’s successful Supreme Court challenge to the patenting of human genes and advised ACLU leadership and staff on a number of other science policy issues. In 2013, Simoncelli was named by the journal Nature as one of “ten people who mattered this year” for her work with the ACLU in overturning gene patents.
Simoncelli is co-author with Sheldon Krimsky of Genetic Justice: DNA Data Banks, Criminal Investigations, and Civil Liberties (Columbia University Press: 2010). She has published articles in a range of scientific, legal and policy journals, including the Journal of the American Medical Association (JAMA), The Journal of Law, Medicine & Ethics (JLME) and Genewatch Magazine.
Simoncelli holds a BA in Biology & Society from Cornell University and an MS in Energy and Resources from the University of California, Berkeley. She has worked as a researcher, analyst, and consultant for a range of nonprofit environmental and social justice organizations, including the Environmental Defense Fund and the Center for Genetics and Society, and served for five years as a board member of the Council for Responsible Genetics.
Tania Simoncelli | Speaker | TED.com